Literature DB >> 19389524

Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference.

Robert E Kalb1, Bruce Strober, Gerald Weinstein, Mark Lebwohl.   

Abstract

BACKGROUND: Methotrexate remains a valuable option for the treatment of psoriasis. This report will summarize studies regarding the use of methotrexate since the last guidelines were published in 1998.
OBJECTIVE: A task force of the National Psoriasis Foundation Medical Board was convened to evaluate treatment options. Our aim was to achieve a consensus on new updated guidelines for the use of methotrexate in the treatment of psoriasis.
METHODS: Reports in the literature were reviewed regarding methotrexate therapy.
RESULTS: A consensus was achieved on use of methotrexate in psoriasis including specific recommendations on dosing and monitoring. The consensus received unanimous approval from members of the Medical Board of the National Psoriasis Foundation. LIMITATIONS: There are few evidence-based studies on the treatment of psoriasis with methotrexate. Many of the reviewed reports are for the treatment of rheumatoid arthritis.
CONCLUSIONS: Methotrexate is a safe and effective drug for the treatment of psoriasis. Appropriate patient selection and monitoring will significantly decrease the risks of side effects. In patients without risk factors for hepatic fibrosis, liver biopsies may not be indicated or the frequency of liver biopsies may be markedly reduced.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389524     DOI: 10.1016/j.jaad.2008.11.906

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  58 in total

1.  An unusual case of acute methotrexate toxicity manifesting as ulcers on psoriatic plaques in an elderly male.

Authors:  G K Singh; Manas Chatterjee; Santanu Banerjee; Sourabh Kumar
Journal:  Med J Armed Forces India       Date:  2013-02-23

2.  Low-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line.

Authors:  Ryan S Funk; Leon van Haandel; Mara L Becker; J Steven Leeder
Journal:  J Pharmacol Exp Ther       Date:  2013-07-25       Impact factor: 4.030

3.  Acute mucocutaneous methotrexate toxicity with marked tissue eosinophilia.

Authors:  Luis J Borda; Andrew Ross; Gabriel Villada; Clara Milikowski
Journal:  BMJ Case Rep       Date:  2018-04-07

4.  Significance of liver biopsy for the evaluation of methotrexate-induced liver damage in patients with rheumatoid arthritis.

Authors:  Tatsuya Osuga; Yoshihiro Ikura; Chikara Kadota; Seiichi Hirano; Yasuhiro Iwai; Takanobu Hayakumo
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 5.  Methotrexate: underused and ignored?

Authors:  Hans H Herfarth; Millie D Long; Kim L Isaacs
Journal:  Dig Dis       Date:  2013-01-03       Impact factor: 2.404

Review 6.  Management of psoriasis patients with hepatitis B or hepatitis C virus infection.

Authors:  Claudio Bonifati; Viviana Lora; Dario Graceffa; Lorenzo Nosotti
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

7.  Deficiency of the Mitochondrial NAD Kinase Causes Stress-Induced Hepatic Steatosis in Mice.

Authors:  Kezhong Zhang; Hyunbae Kim; Zhiyao Fu; Yining Qiu; Zhao Yang; Jiemei Wang; Deqiang Zhang; Xin Tong; Lei Yin; Jing Li; Jianmei Wu; Nathan R Qi; Sander M Houten; Ren Zhang
Journal:  Gastroenterology       Date:  2017-09-18       Impact factor: 22.682

8.  Prevalence and risk factors of methotrexate hepatoxicity in Asian patients with psoriasis.

Authors:  Chong Meng Yeo; Vui Heng Chong; Arul Earnest; Wei Lyn Yang
Journal:  World J Hepatol       Date:  2013-05-27

Review 9.  Inflammatory bowel diseases and human reproduction: a comprehensive evidence-based review.

Authors:  Stefano Palomba; Giuliana Sereni; Angela Falbo; Marina Beltrami; Silvia Lombardini; Maria Chiara Boni; Giovanni Fornaciari; Romano Sassatelli; Giovanni Battista La Sala
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

10.  Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats.

Authors:  Yao Yao; Cong-zhu Ding; Yun Fang
Journal:  Rheumatol Int       Date:  2013-01-19       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.